Lee Ratner
AIDS Malignancy Consortium · Washington University School of Medicine · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lee Ratner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07539454 · Nirogacestat in Patients With Kaposi SarcomaAIDS Malignancy Consortium · recruiting · AIDS-Related Kaposi Sarcoma, Skin Kaposi Sarcoma · principal investigator
- N/ANCT06751355 · Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility TrialWashington University School of Medicine · recruiting · Kaposi Sarcoma · principal investigator
- Ph2NCT06445166 · Propranolol for the Treatment of Kaposi Sarcoma in AdultsWashington University School of Medicine · recruiting · Kaposi Sarcoma · principal investigator
- Ph1NCT04301076 · Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)National Cancer Institute (NCI) · recruiting · Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma · principal investigator
- Ph2NCT02631746 · Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaNational Cancer Institute (NCI) · completed · Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma · principal investigator
- Ph2NCT02137564 · Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi SarcomaAIDS Malignancy Consortium · withdrawn · AIDS-related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma · principal investigator
- Ph2NCT01620736 · Trial to Assess Effect of Raltegravir on HTLV-1 Proviral LoadWashington University School of Medicine · withdrawn · Human T-cell Leukemia Virus Type 1 Infection · principal investigator
- N/ANCT01567722 · Collecting and Studying Tissue Samples From Patients With HIV-Associated MalignanciesAIDS Malignancy Consortium · terminated · Lung Cancer, Lymphoma · principal investigator
- Ph1/Ph2NCT01000285 · EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaWashington University School of Medicine · completed · Leukemia-Lymphoma, Adult T-Cell · principal investigator
- Ph2NCT00041327 · Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/LymphomaAIDS Malignancy Consortium · completed · Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia LymphomaR01CA258359 · NCI · WASHINGTON UNIVERSITY · fiscal years 2022 to 2026 · $360,281 awarded in 2026Same name and institution; not confirmed by an ID
- Project 3: Epigenomic Regulation of HTLV-1 Reactivation & PathogenesisP01CA100730 · NCI · WASHINGTON UNIVERSITY · fiscal years 2008 to 2026 · $479,176 awarded in 2026Same name and institution; not confirmed by an ID
- Molecular Oncology Training GrantT32CA113275 · NCI · WASHINGTON UNIVERSITY · fiscal years 2006 to 2024 · $497,280 awarded in 2024Same name and institution; not confirmed by an ID
- Allosteric integrase inhibitor effects on human T-cell leukemia virus infectionR21AI156014 · NIAID · WASHINGTON UNIVERSITY · fiscal years 2022 to 2023 · $195,626 awarded in 2023Same name and institution; not confirmed by an ID
- Interaction of HTLV-1 Tax & Hbz in TransformationR21CA252869 · NCI · WASHINGTON UNIVERSITY · fiscal years 2021 to 2022 · $216,476 awarded in 2022Same name and institution; not confirmed by an ID
- Role of Protein Kinase C Mutations in Adult T-Cell LeukemiaR21CA255095 · NCI · WASHINGTON UNIVERSITY · fiscal years 2021 to 2022 · $216,476 awarded in 2022Same name and institution; not confirmed by an ID
- Single-Cell Transcriptome & Effect of Immune Checkpoint Therapy on Kaposi SarcomaR21CA257493 · NCI · WASHINGTON UNIVERSITY · fiscal years 2021 to 2022 · $236,250 awarded in 2022Same name and institution; not confirmed by an ID
- IMMUNE CHECKPOINT BLOCKADE PROMOTES ADULT T CELL LEUKEMIAR21CA234640 · NCI · WASHINGTON UNIVERSITY · fiscal years 2019 to 2020 · $205,157 awarded in 2020Same name and institution; not confirmed by an ID
- Developmental Research Program P50CA171963 · NCI · WASHINGTON UNIVERSITY · fiscal years 2013 to 2017 · $76,258 awarded in 2017Same name and institution; not confirmed by an ID
- PROLIFERATIVE EFFECTS OF HTLV-1R01CA063417 · NCI · WASHINGTON UNIVERSITY · fiscal years 1995 to 2017 · $158,641 awarded in 2017Same name and institution; not confirmed by an ID
- ROLE OF CTCF IN HTLV-1 PATHOGENESISR21AI126652 · NIAID · WASHINGTON UNIVERSITY · fiscal years 2016 to 2017 · $242,475 awarded in 2017Same name and institution; not confirmed by an ID
- Imaging NFkB Activation in HTLV LymphomaP50CA094056 · NCI · WASHINGTON UNIVERSITY · fiscal years 2007 to 2016 · $101,413 awarded in 2016Same name and institution; not confirmed by an ID
- HIV CORECEPTOR SHIFTR01AI106361 · NIAID · WASHINGTON UNIVERSITY · fiscal years 2013 to 2014 · $190,000 awarded in 2014Same name and institution; not confirmed by an ID
- CELLULAR RESTRICTIVE FACTOR TARGETED BY VIRAL PROTEIN XR21AI093175 · NIAID · WASHINGTON UNIVERSITY · fiscal years 2011 to 2012 · $228,000 awarded in 2012Same name and institution; not confirmed by an ID
- Interaction of HIV gp120 & G protein coupled receptorsR01AI024745 · NIAID · WASHINGTON UNIVERSITY · fiscal years 1987 to 2007 · $253,876 awarded in 2007Same name and institution; not confirmed by an ID
- Chemo/Antiretroviral therapy for HTLV-1 ATLLR01CA105218 · NCI · WASHINGTON UNIVERSITY · fiscal years 2003 to 2005 · $204,255 awarded in 2005Same name and institution; not confirmed by an ID
- HTLV Receptor Identification and CharacterizationR21CA109678 · NCI · WASHINGTON UNIVERSITY · fiscal years 2004 to 2005 · $137,700 awarded in 2005Same name and institution; not confirmed by an ID
- HIV/SIV Vpx-Invariant chain InteractionR21AI055383 · NIAID · WASHINGTON UNIVERSITY · fiscal years 2003 to 2004 · $351,043 awarded in 2004Same name and institution; not confirmed by an ID
- CHEMO/ANTIRETROVIRAL THERAPY FOR HTLV1 ATLLR21CA093062 · NCI · WASHINGTON UNIVERSITY · fiscal years 2001 to 2002 · $281,916 awarded in 2002Same name and institution; not confirmed by an ID
- HIV1 ASSEMBLY MECHANISM AND INHIBITIONR01CA083659 · NCI · WASHINGTON UNIVERSITY · fiscal years 1999 to 2002 · $254,175 awarded in 2002Same name and institution; not confirmed by an ID
- HIV VPX/VPR STRUCTURE/FUNCTIONR01AI036071 · NIAID · WASHINGTON UNIVERSITY · fiscal years 1995 to 2001 · $281,508 awarded in 2001Same name and institution; not confirmed by an ID
- DOXIL & SDZ PSC 833 AIDS ASSOCIATED KAPOSIS SARCOMAM01RR000036 · NCRR · WASHINGTON UNIVERSITY · fiscal years 1998 to 1999 · $24,436 awarded in 1999Same name and institution; not confirmed by an ID
- ULTRASTRUCTURAL ANALYSIS OF HIV 1 ASSEMBLYR03TW000687 · FIC · WASHINGTON UNIVERSITY · fiscal years 1996 to 1998 · $25,133 awarded in 1998Same name and institution; not confirmed by an ID
- HIV-1 ASSEMBLY--MECHANISM AND INHIBITIONR01AI034736 · NIAID · WASHINGTON UNIVERSITY · fiscal years 1995 to 1997 · $210,928 awarded in 1997Same name and institution; not confirmed by an ID
- VIRAL DETERMINANTS OF HIV 1 ASSOCIATED THROMBOCYTOPENIAR01HL053744 · NHLBI · WASHINGTON UNIVERSITY · fiscal years 1994 to 1996 · $285,230 awarded in 1996Same name and institution; not confirmed by an ID
- AIDS CLINICAL STUDY GROUPU01AI025903 · NIAID · WASHINGTON UNIVERSITY · fiscal years 1987 to 1991 · $1,365,157 awarded in 1991Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Consortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Joseph A. Sparano · fiscal years 2015 to 2026Named on NCT07539454
- PRecision IMaging to Evaluate Kaposi Sarcoma (PRIME-KS)U01CA292765 · NCI · WASHINGTON UNIVERSITY · PI Thomas Odeny, AGGREY SEMWENDERO SEMEERE · fiscal years 2024 to 2026Named on NCT06751355
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT04301076
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2014 to 2019Named on NCT04301076, NCT02631746
- AIDS Malignancy Clinical Trials Consortium (AMC)U01CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RONALD T. MITSUYASU · fiscal years 2006 to 2014Named on NCT02137564, NCT01567722
- AMC OPERATIONS CENTERU01CA070019 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Jeannette Y. Lee · fiscal years 1995 to 2005Named on NCT00041327
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:09 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Laparoscopic assisted live donor nephrectomy--a comparison with the open approach.Transplantation · 1997277 citationsRCR 12.7
- Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.J Clin Oncol · 2001210 citationsRCR 5.2
- Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.N Engl J Med · 2018200 citationsRCR 6.6
- 181 citationsRCR 4.6
- Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.J Clin Oncol · 2002130 citationsRCR 2.9
- Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.Am J Transplant · 2019122 citationsRCR 6.1
- Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.Clin Cancer Res · 2022109 citationsRCR 7.0
- Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.Blood · 201996 citationsRCR 3.3
- AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.Blood · 201573 citationsRCR 2.4
- Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149).J Acquir Immune Defic Syndr · 200066 citationsRCR 1.5